Intercept Pharmaceuticals, Inc. ICPT
Set alert
At close · Nov 7
52-week range unavailable
- Open
- 19.00
- Prev close
- 19.00
- Mkt cap
- 794.69M
- Vol
- 3.91M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.98
- High
- 19.01
- Forward P/E
- 8.88
- Beta
- 0.88
- Short ratio
- 5.54
- Inst. own
- 81.30%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2023
- 50-d avg
- 16.63
- 200-d avg
- 14.55
- 1y target
- 19.00
News
1 year ago reuters.com
Intercept Pharma withdraws liver disease drug from US market
Intercept Pharmaceuticals said on Thursday it is voluntarily withdrawing its liver disease treatment from the U.S. market following a request from the Food and Drug Administration.
1 year ago reuters.com
US FDA says Intercept's drug can cause liver injury in patients without scarring
Intercept Pharmaceuticals' liver disease drug can cause injury to the organ in patients without severe scarring, the U.S. Food and Drug Administration said on Thursday, based on its review of…
1 year ago reuters.com
US FDA declines full approval for Intercept's liver disease drug
The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, raising questions about its future in the market.
1 year ago globenewswire.com
Intercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)
MORRISTOWN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced that the U.S. Food and Drug…
2 years ago reuters.com
FDA advisers vote against confirmatory data for Intercept's liver disease drug
Independent advisers to the U.S. Food and Drug Administration voted on Friday against confirmatory trial data for Intercept Pharmaceuticals' liver disease drug, putting into question the treatment's…
2 years ago reuters.com
FDA staff raises efficacy concerns over Intercept's liver disease drug
The U.S. Food and Drug Administration's staff on Wednesday raised concerns over the efficacy of Intercept Pharmaceuticals' liver disease drug, which is awaiting the regulator's traditional approval.
2 years ago https://www.defenseworld.net
Sophos Group (OTCMKTS:SPHHF) & Loomis AB (publ) (OTCMKTS:LOIMF) Financial Review
Loomis AB (publ) (OTCMKTS:LOIMF – Get Free Report) and Sophos Group (OTCMKTS:SPHHF – Get Free Report) are both business services companies, but which is the better stock? We will compare the two…
2 years ago https://www.zacks.com
Gilead (GILD) Announces Positive Interim Results on PBC Drug
Gilead Sciences, Inc. (GILD Quick QuoteGILD - Free Report) announced positive interim results from the ongoing ASSURE study on pipeline candidate seladelpar.ASSURE is an open-label study evaluating…
2 years ago globenewswire.com
Intercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBC
MORRISTOWN, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and…
2 years ago globenewswire.com
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the…
-
2 years ago businesswire.com
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. ( “Intercept”) announced today the completion of the acquisition of Intercept by…
2 years ago businesswire.com
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
BOLOGNA, Italy--(BUSINESS WIRE)--Alfasigma S.p.A. (“Alfasigma”) announced today that it has, through its wholly owned subsidiary Interstellar Acquisition Inc. (“Interstellar”), successfully completed…
3 years ago zacks.com
Will Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should Know
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 years ago investorplace.com
Stocks to Sell: 7 Overbought Companies You Ought to Dump Right Now
In rough markets it's important to keep and eye out for overbought stocks. Finding the right timing to buy and sell stocks will always be a sought-after skill by any investor searching for that holy…
3 years ago businesswire.com
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intercept…
3 years ago businesswire.com
INTERCEPT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intercept Pharmaceuticals, Inc. - ICPT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intercept…
3 years ago accesswire.com
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept…
3 years ago zacks.com
Intercept Pharmaceuticals (ICPT) Surges on Acquisition Deal
Intercept Pharmaceuticals (ICPT) gains an acquisition deal from Alfasigma for $19.00 per share in cash.
3 years ago zacks.com
Intercept (ICPT) Stock Jumps 79.2%: Will It Continue to Soar?
Intercept (ICPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
3 years ago fool.com
Why Intercept Pharmaceuticals Stock Is Skyrocketing Today
The stock is exploding following an announcement that it's on track to be acquired. Alfasigma is poised to buy Intercept at a price of $19 per share.
-
3 years ago benzinga.com
Why Flux Power Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.
-
3 years ago benzinga.com
Earnings Scheduled For August 2, 2023
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimated to report quarterly earnings at $0.37 per share on revenue of $784.53 million.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 129 stocks made new 52-week lows.
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
Benzinga's Top Ratings Upgrades, Downgrades For May 22, 2023
-
3 years ago benzinga.com
Earnings Scheduled For April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter.
-
3 years ago benzinga.com
Earnings Scheduled For March 2, 2023
Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at $3.03 per share on revenue of $176.89 million.
-
3 years ago benzinga.com
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
-
4 years ago benzinga.com
Earnings Scheduled For November 1, 2022
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion.
-
4 years ago benzinga.com
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
-
4 years ago benzinga.com
Earnings Scheduled For August 3, 2022
Companies Reporting Before The Bell • Fresh Del Monte Produce (NYSE:FDP) is likely to report quarterly earnings at $0.79 per share on revenue of $1.15 billion.
-
4 years ago benzinga.com
Earnings Scheduled For May 6, 2022
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion.
-
4 years ago benzinga.com
Mid-Day Market Update: U.S. Stocks Extend Losses; Dow Dips Over 1,100 Points
U.S. stocks extended losses midway through trading, with the Dow Jones dipping more than 1,100 points on Thursday.
-
4 years ago benzinga.com
Earnings Scheduled For March 2, 2022
Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million.
-
4 years ago benzinga.com
Earnings Scheduled For November 3, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
-
5 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021
Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning, 282 companies set new 52-week lows.
-
5 years ago benzinga.com
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
-
5 years ago benzinga.com
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.
-
5 years ago benzinga.com
70 Biggest Movers From Yesterday
Gainers Pandion Therapeutics, Inc. (NASDAQ: PAND) shares surged 133.4% to close at $59.81 on Thursday after the company announced it will be acquired by Merck for $60 per share in cash.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
During Monday's morning session, 9 stocks hit new 52-week lows.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Before 10 a.m. ET Thursday, 132 stocks made new 52-week lows.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
Stocks That Hit 52-Week Lows On Wednesday
-
7 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Stocks That Hit 52-Week Lows On Thursday
-
7 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Tuesday
-
8 years ago benzinga.com
Stocks Which Set New 52-Week High Yesterday, October 1st
Stocks Which Set New 52-Week High Yesterday, October 1st